闊~ 發問時間: 社會與文化語言 · 6 年前

英文翻譯 急需 10點

Abstract

Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes. Both acute and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2 diabetes mellitus (T2DM). Chronically recurrent hypoglycemia may lead to an impairment of the counterregulatory system, with the potential for the development of hypoglycemia unawareness syndrome, increased severe hypoglycemia-associated hospitalization, and increased mortality. Hypoglycemic events may also have negative implications in cardiovascular disease and/or dementia. Avoidance of hypoglycemia by treating with appropriate, individualized regimens for patients with T2DM should be a primary focus of physicians. Utilizing traditional agents (eg, metformin and thiazolidinediones) that do not promote hypoglycemia, in combination with newer agents such as dipeptidyl peptidase-4 inhibitors and incretin mimetics, could offer a therapeutic advantage when trying to help patients reach their hemoglobin A1c goal without

已更新項目:

the added risk of hypoglycemia.

Keywords: hypoglycemia, type 2 diabetes mellitus, incretin, dipeptidyl peptidase-4 inhibitors, diabetes management

2 個解答

評分
  • 6 年前
    最佳解答

    摘要低血糖是糖尿病患者血糖目標的主要障礙。急性和慢性復發性低血糖事件出現 2 型糖尿病 (2 型糖尿病) 患者有長期的後果。長期經常性低血糖可能導致損害的 counterregulatory 系統,與低血糖無明綜合征、 增加嚴重低血糖症相關住院和死亡率增加的發展潛力。降血糖事件還可能有心血管疾病和 (或) 癡呆的負面影響。避免由適當的、 個人化的治療方案與治療 2 型糖尿病患者低血糖應該是醫師的主要焦點。當試圖説明病人達到糖化血紅蛋白目標沒有利用不促進低血糖,較新的代理,如二肽酶 4 抑制劑和 incretin 類似物,結合的傳統代理商 (eg,二甲雙胍和噻唑) 可以提供治療的優勢

    2014-05-01 17:03:41 補充:

    更大的低血糖危險。關鍵字: 低血糖症、 2 型糖尿病患者、 incretin、 二肽酶 4 抑制劑、 糖尿病管理

    參考資料:
    • 登入以對解答發表意見
  • 匿名使用者
    6 年前

    參考下面的網址看看

    http://phi008780508.pixnet.net/blog

    • 登入以對解答發表意見
還有問題?馬上發問,尋求解答。